Takeda Pharma files patent infringement suit against Dr Reddys, IBN Live News

Takeda Pharma files patent infringement suit against Dr Reddys

PTI | 09:04 PM,Apr 12,2011

Hyderabad, Apr 12 (PTI) Global pharma major Takeda Pharmaceutical Co has filed a patent infringement suit against India�s second largest drug maker Dr Reddy�s Laboratories in a New York Court over the latter�s efforts to manufacture a generic version of acid reflux treatment drug Dexilant (Dexlansoprazole). Takeda alleged that the Indian generic-drug maker and its US subsidiary Dr Reddy�s Laboratories Inc have infringed US Patent Numbers through the submission of an abbreviated new drug application seeking approval to market generic versions of Dexilent, a patented drug of Takeda. Dexilant is used to treat gastroesophageal reflux disease (GERD), a condition in which stomach acid backflows (refluxes) into the esophagus, causing heartburn and possible injury to the esophagus. According to Takeda, the two patents which it alleged Dr Reddy�s infringed would expire in June 2020 and August 2026. Takeda which got the approval from the US FAD to market Dexlansoprazole, changed its name to Dexilent from the earlier Kapidex in March 2010. Takeda further said it got a mandatory notice from Dr Reddy�s on February 21 about their Dexlansoprazole ANDA filing which contained a Paragraph IV certification, a legal assertion that the patents covering Dexilant are invalid. Takeda requested the court to refrain it from manufacturing, sale and distribution and import of the drug. According to reports, US sales of Dexilant delayed-release capsules, 30 mg and 60 mg were about USD20 million and USD261 million, respectively, for the 12 months ending January 2011. When contacted, an official spokesperson of Dr Reddy�s offered no comments.

CNN name, logo and all associated elements ® and © 2012 Cable News Network LP, LLLP. A Time Warner Company. All rights reserved. CNN and the CNN logo are registered marks of Cable News Network, LP LLLP,

displayed with permission. Use of the CNN name and/or logo on or as part of CNN-IBN does not derogate from the intellectual property rights of Cable News Network in respect of them.

Disclaimer: Network18 Media & Investments Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to "Risk Factors" in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.

Disclaimer: TV18 Broadcast Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to "Risk Factors" in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.

Latest news

Takeda Pharma files patent infringement suit against Dr Reddys

Follow us